ViaLase

ViaLase is a clinical-stage ophthalmic device company developing the ViaLuxe Laser System for the noninvasive treatment of open-angle glaucoma. The company's FLigHT procedure utilizes femtosecond laser technology and proprietary imaging to perform a standalone, non-incisional intervention, positioning it as a potential disruptor between ineffective medications and invasive surgeries. With its products not yet for sale pending regulatory clearance, ViaLase is targeting a significant unmet need in a large, chronic disease market dominated by treatments with compliance, efficacy, and safety limitations.

Femtosecond laser system with integrated high-definition imaging for noninvasive, non-incisional creation of apertures in the trabecular meshwork (FLigHT procedure).

ViaLase competes in the crowded glaucoma space against topical pharmaceuticals, laser therapies (e.g., SLT), and a wide array of MIGS devices from companies like Alcon, Johnson & Johnson, and Glaukos. Its key differentiator is the claim of being truly noninvasive and non-incisional, unlike all current MIGS procedures.